An Open Study of the Efficacy of a Single Dose of Ciprofloxacin in Eliminating the Chronic Nasopharyngeal Carriage of Neisseria meningitidis

In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.

Download Full-text

A Trial of Meptazinol for the Relief of Pain after Abdominal Surgery

Anaesthesia and Intensive Care ◽

10.1177/0310057x8000800409 ◽

1980 ◽

Vol 8 (4) ◽

pp. 441-444 ◽

Cited By ~ 3

Author(s):

John M. Gibbs ◽

Helen D. Johnson

Keyword(s):

Single Dose ◽

Side Effects ◽

Abdominal Surgery ◽

Postoperative Analgesia ◽

Open Study ◽

Clinical Impression ◽

Ventilatory Depression

Meptazinol is an opioid drug having mixed agonist-antagonist properties. Chemically it is a hexahydroazepine derivative. It has been used to provide postoperative analgesia1,2 for patients undergoing abdominal surgery but only in single dose studies. The drug is of particular interest in that the clinical impression of minimal ventilatory depression has been confirmed, 3 60 mg meptazinol showing less ventilatory depression than 10 mg of morphine. To test its efficacy in patients undergoing abdominal surgery and to assess the incidence of side effects, an open study was undertaken in 43 patients.

Download Full-text

Single-Dose Therapy of Anogenital and Pharyngeal Gonorrhoea with Ciprofloxacin

International Journal of STD & AIDS ◽

10.1177/095646249200300112 ◽

1992 ◽

Vol 3 (1) ◽

pp. 49-51 ◽

Cited By ~ 7

Author(s):

T Balachandran ◽

A P Roberts ◽

B A Evans ◽

B S Azadian

Keyword(s):

Adverse Reaction ◽

Single Dose ◽

Oral Dose ◽

Neisseria Gonorrhoeae ◽

Treatment Failure ◽

Single Oral Dose ◽

Open Study ◽

Dose Therapy ◽

Single Dose Therapy

A single dose of ciprofloxacin, 250 mg by mouth, was used in an open study to treat pharyngeal or rectal gonorrhoea or both in 64 patients (32 men and 32 women). The study also included 151 men with urethral gonorrhoea and 53 women with cervical or urethral gonorrhoea. Ciprofloxacin cured 63 (98%) patients with pharyngeal or rectal gonorrhoea (including 5 patients with penicillinase-producing Neisseria gonorrhoeae; PPNG), 147 (97%) men with urethral gonorrhoea (including 8 with PPNG) and 52 (98%) women with cervical or urethral gonorrhoea. All the isolates of N. gonorrhoeae were sensitive to 0.03 mg/l of ciprofloxacin. Five of the 6 patients with treatment failure were subsequently cured by a single oral dose of ciprofloxacin 250 mg. None of the patients reported an adverse reaction. Ciprofloxacin 250 mg as a single oral dose is effective and safe in treating patients with pharyngeal or rectal gonorrhoea, including those with PPNG strains.

Download Full-text